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OBJECTIVES The study was done to assess the prevalence of left atrial (LA) chamber and appendage
thrombi in patients with atrial flutter (AFl) scheduled for electrophysiologic study (EPS), to
evaluate the prevalence of thromboembolic complications after transesophageal echocardio-
graphic (TEE)-guided restoration of sinus rhythm and to evaluate clinical risk factors for a
thrombogenic milieu.
BACKGROUND Recent studies showed controversial results on the prevalence of atrial thrombi and the risk
of thromboembolism after restoring sinus rhythm in patients with AFl.
METHODS Between 1995 and 1999, patients with AFl who were scheduled for EPS were included in the
study. After transesophageal assessment of the left atrial appendage and exclusion of thrombi,
an effective anticoagulation was initiated and patients underwent EPS within 24 h.
RESULTS We performed 202 EPSs (radiofrequency catheter ablation, n 5 122; overdrive stimulation,
n 5 64; electrical cardioversion, n 5 16) in 139 consecutive patients with AFl. Fifteen
patients with a thrombogenic milieu were identified. All of them had paroxysmal atrial
fibrillation (AF). Transesophageal echocardiography revealed LA thrombi in two cases (1%).
After EPS no thromboembolic complications were observed. Diabetes mellitus, arterial
hypertension and a decreased left ventricular ejection fraction were found to be independent
risk factors associated with a thrombogenic milieu.
CONCLUSIONS The findings of a low prevalence of LA appendage thrombi (1%) in patients with AFl and a
close correlation between a history of previous embolism and paroxysmal AF support the
current guidelines that patients with pure AFl do not require anticoagulation therapy, whereas
patients with AFl and paroxysmal AF should receive anticoagulation therapy. In addition, the
presence of clinical risk factors should alert the physician to an increased likelihood for a
thrombogenic milieu. (J Am Coll Cardiol 2001;38:778–84) © 2001 by the American
College of Cardiology
Routine anticoagulation therapy is not recommended in
patients with atrial flutter (AFl) undergoing cardioversion
(1). Nevertheless, more recent studies have shown that AFl
may be associated with atrial thrombi and thromboembo-
lism and that thromboembolic events may occur after
cardioversion of AFl (2–5). Therefore, the current guide-
lines state that anticoagulation therapy should be considered
prior to cardioversion of AFl (1). Radiofrequency catheter
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ablation of AFl may allow restoration of sinus rhythm and
is now considered as a curative therapy of chronic AFl
(6–8). However, restoring sinus rhythm by radiofrequency
catheter ablation may cause atrial stunning, with a throm-
bogenic milieu as defined as the induction of spontaneous
echo contrast and depressed mechanical left atrial (LA)
appendage function (9). This thrombogenic milieu may lead
to atrial thrombus formation (10). Therefore, prophylactic
anticoagulation therapy prior to radiofrequency catheter
ablation of AFl has been suggested (9,10).
The aims of this study were: 1) to determine the
prevalence of atrial thrombi in patients with AFl scheduled
for electrophysiologic study (EPS); 2) to analyze the value of
transesophageal echocardiographic (TEE)-guided restora-
tion of sinus rhythm in patients with AFl; and 3) to
correlate clinical and transthoracic echocardiographic
(TTE) parameters with the presence of a thrombogenic
milieu in patients with AFl.
METHODS
Study patients. Between 1995 and 1999 all patients .18
years of age with AFl of $2 days’ duration who underwent
EPS were included in the study. Inclusion criteria were a
history of AFl and an electrocardiographic documentation
of AFl. Exclusion criteria were a recent myocardial infarc-
From the Department of Medicine–Cardiology, University of Bonn, Bonn,
Germany.
Manuscript received October 5, 2000; revised manuscript received March 19, 2001,
accepted June 8, 2001.
Journal of the American College of Cardiology Vol. 38, No. 3, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01463-2
tion and/or cardiothoracic surgery (,30 days) and the
inability to give written informed consent. Written in-
formed consent was obtained from all patients, and the
study was approved by the Institutional Review Board of the
University of Bonn.
Study protocol. All patients were examined clinically, and
both the cardiovascular risk factors (arterial hypertension,
smoking, diabetes mellitus, dyslipoproteinemia and positive
family history) and a history of previous embolism were
assessed. A 12-lead surface electrocardiogram (ECG) was
obtained. To assess LA appendage function and the prev-
alence of echocardiographic markers of thromboembolic
risk, both TTE and TEE were performed ,24 h before
EPS. All patients were followed for four weeks after the
electrophysiological procedure for thromboembolic compli-
cations.
Echocardiographic studies. All studies were conducted
with commercially available equipment (Vingmed 800c,
System V, GE). For TTE, a 3.4-MHz electronic transducer
was used. The M-mode LA dimension and left ventricular
ejection fraction (LVEF) were measured according to rec-
ommendations of the American Society of Echocardiogra-
phy (11).
The TEE procedure was performed with either a 5-MHz
or a 6.7-MHz multiplane electronic or multiplane mechan-
ical transducer as previously reported by our study group
(12,13). Cine loops of the LA and the LA appendage were
stored. The sample volume of the pulsed Doppler was
placed 1 cm into the orifice of the LA appendage, and the
profile of the velocities recorded.
Echocardiographic data analysis. Echocardiographic
evaluations were performed by two independent observers
examining the digitized images after the original examina-
tion. The images were displayed in random order without
clinical information about the patient and were analyzed by
means of the evaluation software provided by the manufac-
turer (Echopac, GE). Interobserver differences were re-
solved by a third observer.
The cine loops of the LA and LA appendage were
examined for thrombi and spontaneous echo contrast. A
thrombus was defined as an echodense intracavitary mass
distinct from the underlying endocardium and not caused by
pectinate muscles (14). The degree of spontaneous echo
contrast was categorized as being either absent (0), mild
(11), mild-to-moderate (21), moderate (31) or severe
(41), on the basis of the system described by Fatkin et al.
(15). The LA appendage area and peak emptying velocities
were measured as previously reported (12).
EPS. Typical AFl was defined by its characteristic 12-lead
surface ECG. This was confirmed at EPS on the basis of
established criteria in those patients who underwent invasive
EPS (8).
RADIOFREQUENCY CATHETER ABLATION OF AFL. Radio-
frequency catheter ablation was performed on patients with
typical AFl in a standard manner, including multipolar
catheters in the His bundle region, coronary sinus and
tricuspid annulus (6,8). Typical AFl with clockwise and
counterclockwise activation of the right atrium was diag-
nosed by demonstrating involvement of the cava-tricuspid
isthmus as an essential part of the macroreentrant circuit.
OVERDRIVE STIMULATION. A Josephson quadripolar cath-
eter (EPT Boston Scientific, San Jose, California) was
placed in the high right atrium, and AFl was treated by high
rate burst pacing starting at 30 ms below tachycardia cycle
length.
EXTERNAL ELECTRICAL CARDIOVERSION. For external
electrical cardioversion, fasting patients received intravenous
(IV) sedation with propofol (1 to 3 mg/kg body weight). A
Physio-Control (Lifepak) direct current (DC) cardioverter
was used in all patients. Incremental DC electrical shocks
were delivered at 200, 300 and 360 J using cutaneous patch
electrodes placed on the chest in the anteroposterior posi-
tion.
Anticoagulation. Patients without effective anticoagula-
tion received IV weight-adjusted heparin (17 U/kg/h)
#24 h prior to the EPS. An activated partial thromboplas-
tin time ratio of 1.5 to 2.5 times of the control value was
achieved by adjusting the dosage. Two hours before the
invasive procedure, heparin was discontinued to minimize
bleeding complications and to allow safe puncture of the
femoral or subclavian vein. After the procedure all sheaths
were removed. Intravenous heparin was reintroduced 4 h
later as a bolus of 5,000 U and readjusted to the level before
the procedure. Heparin was continued for 24 h after the
procedure. Anticoagulation therapy with heparin was not
interrupted in patients undergoing DC cardioversion.
In patients who received coumarin, anticoagulation with
coumarin was discontinued prior to the EPS. Therapy with
heparin was started at weight-adjusted dosage, and the EPS
was performed as mentioned above when the International
Normalized Ratio (INR) was ,1.5. After the procedure,
coumarin therapy was reintroduced and heparin was con-
tinued until the INR was $2.
Statistical analysis. Data are reported as the mean 6 SD.
Continuous variables between groups were compared by a t
Abbreviations and Acronyms
AFl 5 atrial flutter
AF 5 atrial fibrillation
DC 5 direct current
ECG 5 electrocardiogram
EPS 5 electrophysiologic study
INR 5 International Normalized Ratio
IV 5 intravenous
LA 5 left atrium/atrial
LVEF 5 left ventricular ejection fraction
TEE 5 transesophageal echocardiography/
echocardiographic
TTE 5 transthoracic
echocardiography/echocardiographic
779JACC Vol. 38, No. 3, 2001 Schmidt et al.
September 2001:778–84 Thromboembolism and Atrial Flutter
test for unpaired observations. Nominal data were compared
by the chi-square test and/or the Fisher exact test. Categor-
ical data (degree of spontaneous echo contrast) were com-
pared by the Wilcoxon signed rank test for matched pairs.
In all cases, a p value ,0.05 was considered statistically
significant. In addition, 95% confidence intervals (95% CI)
are given. Logistic regression analysis was performed to
evaluate the relationship between the presence of thrombo-
genic milieu defined as existence of spontaneous echo
contrast graded $31 and/or thrombus and clinical (pres-
ence of one risk factor of embolism defined as the presence
of paroxysmal atrial fibrillation [AF], diabetes mellitus,
arterial hypertension and previous embolism) and TTE
markers of thromboembolism (LA diameter .4 cm and
LVEF ,40%).
RESULTS
Patients. A total of 139 patients were included in the
study. Forty patients had two or more repeated EPSs during
the follow-up period. Thus, the number of EPS and
echocardiographic studies totaled 202. Patient data are
provided in Table 1. A total of 114 patients had typical AFl;
25 patients had atypical AFl; 69 patients had $1 episodes of
documented paroxysmal AF; and 38 patients (55%) with
paroxysmal AF received anticoagulation therapy with cou-
marin. An additional 11 patients with pure AFl had
anticoagulation therapy for other reasons. Seven patients
(5%) had a history of previous embolism. Six of those
patients presented with typical AFl. All patients with
history of previous embolism had a history of paroxysmal
AF.
Echocardiography. Measurements are given in Table 2.
The flow velocity profile over the LA appendage showed a
regular sawtooth pattern corresponding to the flutter waves
of the ECG.
Prevalence of spontaneous echo contrast and thrombi.
Spontaneous echo contrast was found in 56 cases (28%) of
202 TEE studies: 24 patients had grade 11 (12%), 17 had
grade 21 (8%), 10 had grade 31 (5%) and 5 had grade 41
(2%). Out of 202 TEE studies, 2 (1%) thrombi were found.
The thrombi measured 0.8 cm 3 0.6 cm and 0.6 cm 3
0.4 cm and were located in the tip of the LA appendage.
The two patients with thrombi had congestive heart failure
with a LVEF of 0.30 (Patient 1, Table 3) and 0.46 (Patient
8, Table 3), respectively. Both patients had paroxysmal AF.
An attempt to restore sinus rhythm was not performed in
the latter patients. Both patients were treated with phen-
procoumon. During the follow-up, one patient developed
persistent AF. In both cases the thrombi disappeared on
repeated TEE examination. Neither of those patients had
clinical signs of thromboembolism.
Comparison of patients with typical and atypical AFl.
Patients with atypical and typical AFl did not differ in LA
diameter (4.3 6 0.64 vs. 4.4 6 0.64; p 5 0.68; 0.95% CI
20.3 to 0.2; LVEF (54.3 6 10.6; p 5 0.24; 95% CI 21.7 to
Table 1. Patient Characteristics
Total
Typical Atrial
Flutter
Atypical Atrial
Flutter p Value
Number 139 114 25
Age 60 6 12 61 6 12 57 6 12 0.18
Male gender 121 (87%) 98 (86%) 23 (92%) 0.42
Clinical risk factors
Arterial hypertension 53 (38%) 42 (37%) 11 (44%) 0.50
Smoking 48 (35%) 38 (33%) 10 (40%) 0.53
Dyslipoproteinemia 71 (51%) 60 (53%) 11 (44%) 0.43
Diabetes mellitus 30 (22%) 25 (22%) 5 (20%) 0.83
Positive family history 20 (14%) 17 (15%) 3 (12%) 0.71
Previous embolism 7 (5%) 6 (5%) 1 (4%) 0.79
Underlying heart diesease
Coronary artery disease 41 (29%) 36 (32%) 5 (20%) 0.25
Congenital heart disease 3 (2%) 3 (2.6%) 0 0.41
Valular heart disease 11 (8%) 10 (9%) 1 (4%) 0.42
Cardiomyopathy 8 (6%) 7 (6.1%) 1 (4%) 0.68
Other 4 (3%) 3 (3%) 1 (4%) 0.71
None 45 (32%) 35 (31%) 10 (40%) 0.37
Duration of atrial flutter 36 (26%) 31 (27%) 5 (20%) 0.46
(,3 months)
Age is expressed as mean 6 SD. Remaining data are given as number (%) of patients.
Table 2. Comparison of Patients With Pure AFl and Patients
With Paroxysmal AF
Paroxysmal AF Pure AFl p Value 95% CI
Number 69 70
LA diameter 4.4 6 0.6 4.3 6 0.6 0.49 20.12–0.24
LVEF 52 6 10 52 6 13 0.70 20.13–2.6
LAA max 4.5 6 1.6 3.9 6 1.3 0.016 0.13–1.2
LAAv 0.52 6 0.25 0.55 6 0.2 0.45 20.1–0.05
SEC 0.83 6 1.2 0.5 6 0.9 0.06 20.02–0.68
AF 5 atrial fibrillation; AFl 5 atrial flutter; CI 5 confidence interval; LA 5 left
atrial; LAA max 5 maximal left atrial appendage area; LAAv 5 peak emptying
velocities of the left atrial appendage; LVEF 5 left ventricular ejection fraction;
SEC 5 spontaneous echo contrast.
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6.8); maximal area of the LA appendage (4.4 6 1.6 vs. 4.2
6 1.5; p 5 0.57; 95% CI 20.48 to 0.86); peak emptying
velocities of the LA appendage (0.51 6 0.26 vs. 0.54 6
0.22; p 5 0.57; 95% CI 20.12 to 0.07); and the degree of
spontaneous echo contrast (0.68 6 1.1 vs. 0.69 6 1.1; p 5
0.95; 95% CI 20.47 to 0.44).
Comparison of patients with pure AFl and patients with
paroxysmal AF. Patient data are given in Table 2. Patients
with pure AFl and patients with paroxysmal AF did not
differ significantly in LA diameter (95% CI 20.12 to 0.24),
LVEF (95% CI 20.13 to 0.05) and the degree of sponta-
neous echo contrast appendage (95% CI 20.1 to 0.05) and
the degree of spontaneous echo contrast (95% CI 20.02 to
0.68). However, the maximal LA appendage area (95% CI
0.13 to 1.2) was significantly larger in patients with parox-
ysmal AF. Patients with paroxysmal AF more often had a
history of previous embolism than did patients with pure
AFl (p 5 0.01).
Electrophysiologic treatment. The EPS consisted of 122
radiofrequency catheter ablations, 64 overdrive stimulation
procedures and 16 electrical cardioversions. Sinus rhythm
was restored in 160 cases (79%). Radiofrequency catheter
ablation was successful in 106 cases (87%), overdrive stim-
ulation in 42 cases (66%) and cardioversion resulted in the
restoration of sinus rhythm in 12 cases (75%). Thrombo-
embolism was not observed during the follow-up period.
Relationship between clinical and TTE markers of
thromboembolic risk and transesophageal parameters of
a thrombogenic milieu. A thrombogenic milieu—as de-
fined as either the presence of thrombus or dense sponta-
neous echo contrast—was found in 15 of 202 studies (7%).
Table 3 gives the individual values of those patients.
Previous embolism (p 5 0.75), paroxysmal AF (p 5 0.1)
and a LA diameter .40 mm (p 5 0.98) were not signifi-
cantly correlated to a thrombogenic milieu. However, pa-
tients without thrombogenic milieu may also present with
considerably enlarged LA. The sensitivity of an enlarged
LA diameter for the presence of a thrombogenic milieu was
100%, whereas the specifity was only 36%.
A decreased ejection fraction ,40% (p 5 , 0.0002,
relative risk 5 8.4, 95% CI 2.7 to 26.2), the presence of
diabetes mellitus (p 5 0.0004, relative risk 5 7.4, 95% CI
2.4 to 22.8) and a history of arterial hypertension (p 5
0.002, relative risk 5 8.1, 95% CI 2.2 to 30.2) were
significantly correlated with the presence of a thrombogenic
milieu. Logistic regression analysis revealed that all param-
eters were independent risk factors.
All 15 patients with a thrombogenic milieu had at least
one clinical risk factor. Four patients (27%) had three
clinical risk factors, ten (66%) had two clinical risk factors
and one patient (7%) had only one clinical risk factor. In
addition, 7 out of the 15 patients (47%) had a LVEF ,40%.
DISCUSSION
The primary findings of our study are: 1) that LA thrombi
are uncommon in patients with AFl scheduled for EPS; 2)
that TEE-guided restoration of sinus rhythm in conjunc-
tion with short-term periprocedural anticoagulation is safe
in patients with AFl; and 3) that the presence of diabetes
mellitus, arterial hypertension and a LVEF ,40% were
independent parameters for predicting the presence of a
thrombogenic milieu in patients with AFl.
LA appendage morphology and function in patients with
AFl. Use of TEE may allow detection of a thrombogenic
milieu (15,16). Reduced peak emptying velocities of the LA
appendage and the presence of dense spontaneous echo
contrast have been correlated with an increased thrombo-
embolic risk in patients with AF (15,17). However, there
are only few studies correlating those parameters with the
thromboembolic risk in patients with AFl (3,18). In accor-
dance with previous reports, our study found that patients
with AFl have a regular flow velocity profile over the LA
appendage (19,20). Spontaneous echo contrast was found in
Table 3. Individual Clinical and Echocardiographic Parameters of Patients With a Thrombogenic Milieu
Patient
No.
Age
(yrs)
Clinical Parameters Echocardiographic Parameters
Diabetes
Mellitus
Arterial
Hypertension
Previous
Embolism
Paroxysmal
AF
LAD
(cm)
LVEF
(%)
LAAv
(m/s) SEC Thrombus
1 67 Yes No No Yes 5.6 30 0.15 3 Yes
2 67 Yes Yes No No 6.2 24 0.40 3 No
3 73 Yes Yes No Yes 4.3 50 0.50 3 No
4 73 Yes Yes No Yes 4.3 50 0.35 3 No
5 67 Yes Yes No No 6.5 24 0.20 3 No
6 68 No Yes No Yes 4.2 50 0.28 4 No
7 60 Yes Yes No No 5.5 34 0.24 3 No
8 58 No Yes No Yes 5.0 46 0.23 4 Yes
9 67 Yes No No Yes 5.5 30 0.12 3 No
10 77 Yes Yes No No 4.1 44 0.71 3 No
11 68 No No No Yes 4.7 55 0.20 3 No
12 63 No Yes No Yes 5.6 40 0.15 4 No
13 78 No Yes Yes Yes 5.2 41 0.22 4 No
14 53 Yes Yes No Yes 5.3 33 0.18 4 No
15 52 No Yes No Yes 4.8 37 0.58 3 No
See Table 2 for abbreviations.
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56 cases of 202 echocardiographic studies (28%). However,
only 15 (7%) of the latter patients had dense spontaneous
echo contrast, whereas the remaining patients (n 5 41) had
only mild or moderate spontaneous echo contrast.
Another important result of our study is that we found
only 2 thrombi out of 202 echocardiographic studies (1%).
This finding of a low prevalence of thrombi in patients with
AFl accords with four other studies that did not find
thrombi in patients with AFl (5,9,10,18). Nevertheless,
more recent echocardiographic studies found a higher prev-
alence of LA thrombi and spontaneous echo contrast in
patients with AFl. Thus, there is conflicting evidence of the
prevalence of LA thrombi and spontaneous echo contrast in
patients with AFl. One study found 5 thrombi in 47
patients and spontaneous echo contrast in 32% of the
patients (3). However, 26 % of those patients had heart
failure, and an abnormal left ventricular function was
present in 53%, whereas in our study only 11% of the
patients had a LVEF ,40%. Furthermore, 10% of the
patients of the previous study had a prior cerebrovascular
accident. Thus, the patients in the study by Irani et al. (3)
had an increased risk of atrial thrombi irrespective of the
underlying arrhythmia. Another study found 2 thrombi in
30 patients and spontaneous echo contrast in 25% of the
patients (21). It is interesting that the latter study did not
find a difference in LVEF between patients with and
without spontaneous echo contrast. However, the patient
number was limited. Another possible explanation for the
lower prevalence of thrombi in our patient cohort might be
that 55% of patients with AFl and paroxysmal AF were
anticoagulated. Nevertheless, the low prevalence of thrombi
and spontaneous echo contrast in our study supports the
results of earlier reports demonstrating a low prevalence of
thromboembolic complications in patients with AFl (22–
26).
Comparison of patients with pure AFl and patients with
paroxysmal AF. Patients with pure AFl are regarded to
have a lower thromboembolic risk than are patients with
AFl and paroxysmal AF. Thus, the current guidelines for
anticoagulation therapy recommend anticoagulation therapy
in patients with AFl and paroxysmal AF. The results of our
study show that patients with pure AFl and patients with
AFl and paroxysmal AF did not differ significantly in LA
diameter, LVEF, peak emptying velocities of the LA
appendage, maximal area of the LA appendage and the
degree of spontaneous echo contrast. Thus, the echocardio-
graphic markers of thromboembolic risk did not differ for
patients with pure AFl and those with paroxysmal AF. This
result seems to contradict the finding of previous studies
showing that AF is often correlated with a thrombogenic
milieu. However, it has to be recognized that our TEE
studies were not conducted during episodes of AF. It is
possible that the conversion of AFl to AF may induce or
worsen a thrombogenic milieu. Nevertheless, all seven
patients with a history of previous embolism had paroxysmal
AF. Furthermore, 11 of 15 (73%) patients with a throm-
bogenic milieu had paroxysmal AF, and both patients with
thrombi had paroxysmal AF. A possible explanation for the
relatively low prevalence of thrombi in patients with parox-
ysmal AF may be that most of the patients with paroxysmal
AF were anticoagulated.
Comparison of patients with atypical and typical AFl.
The findings of our study show that patients with typical
and atypical AFl did not differ in LA diameter, LVEF, peak
emptying velocities of the LA appendage, maximal area of
the LA appendage and the degree of spontaneous echo
contrast, indicating that the echocardiographic markers of
thromboembolic risk were not different between the two
groups. Thus, the type of AFl does not seem to influence
the thromboembolic risk in patients with AFl.
Thromboembolism after TEE-guided electrophysiologic
restoration of sinus rhythm in patients with AFl. Trans-
esophageal echocardiography has a high accuracy for iden-
tifying atrial thrombi (27). Furthermore, a TEE-guided
approach of cardioversion of AF in concert with periproce-
dural therapeutic anticoagulation has been shown to have a
similar safety profile to that of conventional therapy (28,29).
However, the value of TEE prior to electrophysiologic
treatment in patients with AFl has not yet been investi-
gated. The results of our study show that after TEE
exclusion of LA thrombi and short-term periprocedural
anticoagulation with heparin, no thromboembolic compli-
cations were observed after restoration of sinus rhythm.
This finding agrees with an earlier study that demonstrated
a low thromboembolic risk after restoration of sinus rhythm
even without anticoagulation therapy (22). However, the
findings of the latter study and our results are in contrast
with more recent studies reporting a higher prevalence of
thromboembolic complications after restoration of sinus
rhythm (2,4,5). Nevertheless, those studies included only a
small number of selected patients. Furthermore, most pa-
tients in those studies did not receive periprocedural anti-
coagulation therapy.
Recent studies showed that radiofrequency catheter ab-
lation of AFl may be associated with a postprocedural atrial
stunning (9,10). One study could also demonstrate that the
postprocedural atrial stunning was associated with the
generation of a new atrial thrombus after successful radio-
frequency catheter ablation therapy for AFl (9). Conse-
quently, it was suggested to anticoagulate patients with
chronic AFl undergoing radiofrequency catheter ablation.
The results of our study demonstrate that radiofrequency
catheter ablation may be performed safely in patients in
whom thrombi were excluded by TEE and who received
periprocedural anticoagulation therapy.
Relationship between clinical and echocardiographic
thromboembolic risk factors and a thrombogenic milieu.
Previous studies have shown that the presence of a throm-
bogenic milieu is associated with an increased thromboem-
bolic risk in patients with AF (16,30). In addition, large
multicenter studies have shown that clinical and TTE
parameters may allow estimation of the thromboembolic
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risk in patients with AF (31–33). The most important risk
factors are a history of previous embolism, a history of
arterial hypertension, diabetes mellitus, an enlarged LA and
decreased LVEF. The results of our study show that a
history of previous embolism and an enlarged LA were not
associated with a thrombogenic milieu in the LA in patients
with AFl. The finding of our study that an enlarged LA was
not specific for a thrombogenic milieu accords with more
recent results showing that an enlarged LA is not indicative
of an increased thromboembolic risk in patients with AF
(34). An interesting result of our study was that the presence
of diabetes mellitus, a history of arterial hypertension and a
decreased LVEF was significantly associated with the pres-
ence of a thrombogenic milieu. The finding of an increased
risk of a thrombogenic milieu in patients with decreased
LVEF is in agreement with the finding of a previous study
showing that patients with a LVEF ,40% have a higher
prevalence of atrial thrombi (35). In our study, all patients
with a thrombogenic milieu had at least one clinical risk
factor. In addition, 47% of the patients had a LVEF ,40%.
Because the presence of clinical risk factors and/or a
decreased LVEF is closely associated with a thrombogenic
milieu, those patients should receive a TEE examination to
exclude atrial thrombi before restoration of sinus rhythm.
Clinical implications. The finding of our study that the
prevalence of LA thrombi is low in patients with AFl
scheduled for EPS supports the current guidelines that
patients with pure AFl should not automatically receive
anticoagulation therapy. The result of our study that those
patients with paroxysmal AF had significantly more often a
history of previous embolism than did those patients with
pure AFl underlines the importance of anticoagulation
therapy in patients with AFl and paroxysmal AF. Patients
with paroxysmal AF should be considered to receive long-
term anticoagulation therapy.
The results of our study demonstrate that TEE-guided
restoration of sinus rhythm in conjunction with short-term
periprocedural anticoagulation with heparin in patients with
AFl is safe. Therefore, this procedure may be suggested to
prevent thromboembolic complications after electrophysi-
ologic treatment of AFl.
The finding that the presence of diabetes mellitus, arterial
hypertension and a decreased LVEF (,40%) is associated
with a thromboembolic milieu allows clinical and TTE risk
stratification of patients with AFl and should alert the
physician of an increased likelihood of atrial thrombi.
Study limitations. This study was a large prospective
observational study of patients with AFl scheduled for EPS.
However, patients were not randomized to receive antico-
agulation therapy prior to restoring sinus rhythm. Thus, the
impact of the periprocedural anticoagulation therapy may
not be ultimately defined.
Finally, because the number of patients with a history of
embolism was small, the statistical power to detect a
correlation between previous embolism and a thrombogenic
milieu is limited.
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